Diagnosis and Treatment > Investigation > Polysomnography

You are looking at 1 - 2 of 2 items

Mads Ryø Jochumsen Department of Nuclear Medicine & PET Centre, Aarhus University Hospital, Aarhus, Denmark

Search for other papers by Mads Ryø Jochumsen in
Google Scholar
PubMed
Close
,
Peter Iversen Department of Nuclear Medicine & PET Centre, Aarhus University Hospital, Aarhus, Denmark

Search for other papers by Peter Iversen in
Google Scholar
PubMed
Close
, and
Anne Kirstine Arveschoug Department of Nuclear Medicine & PET Centre, Aarhus University Hospital, Aarhus, Denmark

Search for other papers by Anne Kirstine Arveschoug in
Google Scholar
PubMed
Close

Summary

A case of follicular thyroid cancer with intense focal Methionine uptake on 11C-Methionine PET/CT is reported here. The use of 11C-Methionine PET in differentiated thyroid cancer is currently being investigated as a surrogate tracer compared to the more widely used 18F-FDG PET. This case illustrates the potential incremental value of this modality, not only in the localizing of parathyroid adenoma, but also indicating that 11C-Methionine PET might have a potential of increasing the pretest likelihood of thyroid malignancy in a cold nodule with highly increased Sestamibi uptake.

Learning points:

  • 11C-Methionine PET/CT and 18F-Fluorocholine PET/CT often visualizes the parathyroid adenoma in case of negative Tc-99m-MIBI SPECT/CT.

  • A cold nodule in Tc-99m Pertechnetat thyroid scintigraphy with a negative Sestamibi scintigraphy has a very low probability of being malignant.

  • However, the pretest likelihood of thyroid cancer in a cold nodule with increased Sestamibi uptake is low.

  • 11C-Methionine PET might have a potential incremental value in increasing the pretest likelihood of thyroid malignancy in a cold nodule with highly increased Sestamibi uptake.

Open access
Maria Cabrer Endocrine Unit, Hospital Comarcal d’Inca, Inca, Spain

Search for other papers by Maria Cabrer in
Google Scholar
PubMed
Close
,
Guillermo Serra Endocrine Unit, Hospital Universitari Son Espases, Palma, Spain

Search for other papers by Guillermo Serra in
Google Scholar
PubMed
Close
,
María Soledad Gogorza Endocrine Unit, Hospital Universitari Son Espases, Palma, Spain

Search for other papers by María Soledad Gogorza in
Google Scholar
PubMed
Close
, and
Vicente Pereg Endocrine Unit, Hospital Universitari Son Espases, Palma, Spain

Search for other papers by Vicente Pereg in
Google Scholar
PubMed
Close

Summary

Chromosome 22q11.2 deletion syndrome (22q11.2DS) is a genetic syndrome that may present with hypocalcemia due to primary hypoparathyroidism (PH) at any age. We report a new diagnosis of 22q11.2DS in a 57-year-old man who presented with symptomatic hypocalcemia. It is important to consider genetic causes of hypocalcemia due to PH regardless of age.

Learning points:

  • It is important to discard genetic cause of primary hypoparathyroidism in a patient without autoimmune disease or prior neck surgery.

  • A new diagnosis of a hereditary disease has familial implications and needs genetic counselling.

  • It is also important to discard other syndrome’s comorbidities.

Open access